🚀 VC round data is live in beta, check it out!
Hofseth BioCare Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hofseth BioCare and similar public comparables like Biome Australia, Enzymatica, Provexis, Valbiotis and more.
Hofseth BioCare Overview
About Hofseth BioCare
Hofseth BioCare ASA is a Norway-based company engaged in the business of developing, manufacturing, marketing, and selling marine ingredients such as oil, calcium, and protein products. Its products and their respective brands include salmon oil (OmeGo), hydrolyzed soluble protein (ProGo), Calcium/Collagen (CalGo or NT-II), and non-soluble protein (PetGo), all of which are produced in the Midsund plant. The firm sells its products to various segments of the human nutrition market, such as sports nutrition, supplements, and health foods, as well as to the market within nutrition for the pet and feed industry. It generates maximum revenue from the sale of salmon oil. Geographically, the company generates maximum revenue from Europe, followed by North America and Asia.
Founded
2009
HQ
Employees
78
Website
Financials (FY)
EV
$85M
Hofseth BioCare Financials
Hofseth BioCare reported last fiscal year revenue of $27M and negative EBITDA of ($8M).
In the same fiscal year, Hofseth BioCare generated $10M in gross profit, ($8M) in EBITDA losses, and had net loss of ($14M).
Hofseth BioCare P&L
In the most recent fiscal year, Hofseth BioCare reported revenue of $27M and EBITDA of ($8M).
Hofseth BioCare expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $27M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $10M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($8M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (28%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (44%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($14M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (53%) | XXX | XXX | XXX |
| Net Debt | — | — | $20M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hofseth BioCare Stock Performance
Hofseth BioCare has current market cap of $53M, and enterprise value of $85M.
Market Cap Evolution
Hofseth BioCare's stock price is $0.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $85M | $53M | -0.1% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHofseth BioCare Valuation Multiples
Hofseth BioCare trades at 3.1x EV/Revenue multiple, and (10.9x) EV/EBITDA.
Hofseth BioCare Financial Valuation Multiples
As of April 19, 2026, Hofseth BioCare has market cap of $53M and EV of $85M.
Equity research analysts estimate Hofseth BioCare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hofseth BioCare has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $53M | XXX | $53M | XXX | XXX | XXX |
| EV (current) | $85M | XXX | $85M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (7.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.3x | XXX | XXX | XXX |
| P/E | — | XXX | (3.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (16.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hofseth BioCare Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hofseth BioCare Margins & Growth Rates
Hofseth BioCare's revenue in the last fiscal year declined by (0%).
Hofseth BioCare's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Hofseth BioCare Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (28%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 4% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 81% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hofseth BioCare Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hofseth BioCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Biome Australia | XXX | XXX | XXX | XXX | XXX | XXX |
| Enzymatica | XXX | XXX | XXX | XXX | XXX | XXX |
| Provexis | XXX | XXX | XXX | XXX | XXX | XXX |
| Valbiotis | XXX | XXX | XXX | XXX | XXX | XXX |
| FitLife Brands | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hofseth BioCare M&A Activity
Hofseth BioCare acquired XXX companies to date.
Last acquisition by Hofseth BioCare was on XXXXXXXX, XXXXX. Hofseth BioCare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hofseth BioCare
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHofseth BioCare Investment Activity
Hofseth BioCare invested in XXX companies to date.
Hofseth BioCare made its latest investment on XXXXXXXX, XXXXX. Hofseth BioCare invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hofseth BioCare
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hofseth BioCare
| When was Hofseth BioCare founded? | Hofseth BioCare was founded in 2009. |
| Where is Hofseth BioCare headquartered? | Hofseth BioCare is headquartered in Norway. |
| How many employees does Hofseth BioCare have? | As of today, Hofseth BioCare has over 78 employees. |
| Is Hofseth BioCare publicly listed? | Yes, Hofseth BioCare is a public company listed on Oslo Børs. |
| What is the stock symbol of Hofseth BioCare? | Hofseth BioCare trades under HBC ticker. |
| When did Hofseth BioCare go public? | Hofseth BioCare went public in 2011. |
| Who are competitors of Hofseth BioCare? | Hofseth BioCare main competitors are Biome Australia, Enzymatica, Provexis, Valbiotis. |
| What is the current market cap of Hofseth BioCare? | Hofseth BioCare's current market cap is $53M. |
| What is the current revenue of Hofseth BioCare? | Hofseth BioCare's last fiscal year revenue is $27M. |
| What is the current EV/Revenue multiple of Hofseth BioCare? | Current revenue multiple of Hofseth BioCare is 3.1x. |
| Is Hofseth BioCare profitable? | No, Hofseth BioCare is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.